Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

High dose interleukin-2 (IL-2) is active against metastatic melanoma and renal cell carcinoma, but treatment-associated toxicity and expansion of suppressive regulatory T cells (Tregs) limit its use in patients with cancer. Bempegaldesleukin (NKTR-214) is an engineered IL-2 cytokine prodrug that pro...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Nat Commun
Κύριοι συγγραφείς: Sharma, Meenu, Khong, Hiep, Fa’ak, Faisal, Bentebibel, Salah-Eddine, Janssen, Louise M. E., Chesson, Brent C., Creasy, Caitlin A., Forget, Marie-Andrée, Kahn, Laura Maria S., Pazdrak, Barbara, Karki, Binisha, Hailemichael, Yared, Singh, Manisha, Vianden, Christina, Vennam, Srinivas, Bharadwaj, Uddalak, Tweardy, David J., Haymaker, Cara, Bernatchez, Chantale, Huang, Shixia, Rajapakshe, Kimal, Coarfa, Cristian, Hurwitz, Michael E., Sznol, Mario, Hwu, Patrick, Hoch, Ute, Addepalli, Murali, Charych, Deborah H., Zalevsky, Jonathan, Diab, Adi, Overwijk, Willem W.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Nature Publishing Group UK 2020
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6994577/
https://ncbi.nlm.nih.gov/pubmed/32005826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-020-14471-1
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια